RNA
Avidity Biosciences Inc.
Company Overview
| Mkt Cap | $8.98B | Price | $72.74 |
| Volume | 1.40M | Change | +0.23% |
| P/E Ratio | -27.9 | Open | $72.55 |
| Revenue | $10.9M | Prev Close | $72.57 |
| Net Income | $-322.3M | 52W Range | $21.51 - $72.74 |
| Div Yield | N/A | Target | $73.83 |
| Overall | 61 | Value | 40 |
| Quality | 60 | Technical | 83 |
No chart data available
About Avidity Biosciences Inc.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Latest News
SPY ETF Daily Update, 2/3/2026
Moderna’s CMV Vaccine Extension Study Reaches Completion, Setting the Stage for Next Growth Catalyst
SNDK, MU, CRM: January’s Best and Worst-Performing Stocks
Moderna Stock Slips As Ambitious Cancer Trials Drag On
Alterity Sharpens ATH434 Phase 3 Plans as Phase 2 MSA Data Strengthen
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RNA | $72.74 | +0.2% | 1.40M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Avidity Biosciences Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW